Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — Investor Presentation (February 2022)
34 slides from Nemaura Medical's investor presentation, Feb 11, 2022
Slide 1: Corporate Presentation 11th February 2022
Corporate Presentation 11 th February 2022 Nasdaq : NMRD
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura’s short - term and long - term growth strategies, can sometimes be identified by use of terms su
Slide 3: Clinical Need
Clinical Need… There are over 463 million people living with diabetes worldwide, and over $ 760 Billion was spent in the U . S . alone in 2019 for diabetes related healthcare expenditure 1 . The total addressable market exceeds $ 150 Billion 2 , 3 , 4 . Obesity and Diabetes are two of the major driv
Slide 4: Why CGM? BGM Misses the full picture!
Why CGM? BGM Misses the full picture!
Slide 5: Nemaura's Vision
Nemaura’s Vision Lead in the Prevention, Management, & Reversal of Type 2 Diabetes using a low - cost, flexible, user - friendly device and digital ecosystem.
Slide 6: Our Approach
Our Approach ▪ Skin mounted (disposable) sensor & (non - disposable) transmitter. Glucose extracted to the surface of the skin ▪ Sensors use well established glucose Oxidase enzyme to convert glucose to an electric current signal ▪ Low energy Bluetooth sends this to the phone app every 5 minutes whe
Slide 7: Product Positioning
Product Positioning sugarBEAT® CGM – Direct sales to consumers that wish to purchase sensors to measure glucose profiles on days they choose. www.sugarBEAT.com BEAT®diabetes Program: A diabetes management program based on subscription. Currently in Pilot and plan is to sell in to Corporates and Insu
Slide 8: Product Positioning: sugarBEAT licensee sales
Product Positioning sugarBEAT® CGM sales through Licensee(s) – no further marketing spend required on Nemaura’s part thus minimizing cost of sales. Transmitter devices are sold at cost to the licensee (razorblade model) and the sensors at an agreed price of 12.50 Euros per box of 5 sensors in Europe
Slide 9: Product Positioning: Miboko
Product Positioning Miboko ® Consumer Metabolic Health Program – Direct to Employers and Insurers & Direct to consumer. What purpose does it serve? It builds on the rapidly growing self - care and preventative digital medicine category that both employers and insurers are more commonly embracing. Wh
Slide 10: Product Positioning - Competition
Product Positioning - Competition What about the sensors that are currently being developed by competitors such as BioLinq , PK Vitality, Sano (acquired by One drop) etc., all of whom are using Microneedles coated with enzymes and polymers? Whilst academic papers and pilot humans studies have shown
Slide 11: Challenges of Microneedles
Challenges: ▪ Keeping one needle in the skin is challenging, but when you have dozens of needles the challenge is multiplied. ▪ Needles have to stay in the skin to a given depth for the duration of sensing from 1 to 5 days. Generally keeping microneedles in the skin for more than a few hours is chal
Slide 12: Light based sensors
What about light based sensors being developed for various wrist worn devices? ▪ Light/optical based technologies have been in development for around 30 years without much success due to the lack of specificity and signal to noise issues as well as prohibitive device costs. ▪ To add to this there is
Slide 13: sugarBEAT Regulatory Status
sugarBEAT ® Regulatory Status ▪ CE Approved Class 2b Medical Device in Europe ▪ FDA PMA submitted and in review • FDA Bio - monitoring Division (BIMO) Audit conducted in December 2021 at Nemaura’s UK facility. A single 483 observation was issued. Company submitted a full and complete response to FDA
Slide 14: sugarBEAT Sales status UK
sugarBEAT ® Sales status UK ▪ UK: 200,000 Sensors ordered by licensee following soft launch success ▪ Delivered first batch of Transmitter devices in December 2021, with rolling bi - weekly/monthly delivery planned. ▪ Purchase order forecast for (approximately) a further 100,000 per month for the ne
Slide 15: sugarBEAT Outside-UK
sugarBEAT ® Outside - UK Planning direct to consumer launch of sugarBEAT outside of UK where CE approval is accepted, such as Europe and Middle East.
Slide 16: sugarBEAT How it works
sugarBEAT” Ee me Samantha How it works JY Youre in your target ronge 09:03 6.2 See changes as they happen s Helps you understand vty ono your unique glucose 2 ice Ga ED & a trend line and lifestyle choices taken.
Slide 17: sugarBEAT technology
sugarBEAT ® Nemaura’s technology does not use Reverse iontophoresis . It is based on causing the skin to temporarily enhance its permeation using a microsystems based fabricated disposable patch, such that glucose diffuses through the skin at a constant rate during sensor use . The glucose is collec
Slide 18: sugarBEAT Testimonials
sugarBEAT ® Testimonials My Sugar Watch offered me a needle - free blood glucose monitoring solution that’s non - invasive and easy to use. I didn’t even realize I had the My Sugar watch device on my arm as it is so lightweight. It gives me the assurance that my blood sugar reading is accurate, and
Slide 19: sugarBEAT Testimonials: volunteer data
sugarBEAT ® Testimonials Example of Volunteer data compared with BGM and Invasive CGM Blue: Finger Prick BGM (Blood glucose meter) Red: Invasive CGM sugarBEAT® Raw data presented (prior to algorithmic conversion, demonstrating tight correlation)
Slide 20: Diabetes prevention and management program launched in the U.S.
Type 2 Diabetes prevention and management program launched in the U.S.
Slide 21: BEAT diabetes – Components
BEAT ® diabetes – 3 Components ▪ Weight loss program originally developed at the Joslin Diabetes Centre – over 12 years of clinical evidence (based on an in - clinic program, subsequently replicated using a virtual program). Sustained long term weight loss achieved without loss of muscle mass ▪ proB
Slide 22: Miboko Mind Body Konnect
Miboko MIND BODY KONNECT A metabolic health program comprising an app and integrated glucose sensor
Slide 23: In essence
In essence: We have a unique sensor that allows an insight into one of the most fundamental functions of the human body: the ability to regulate blood glucose levels & thus the level of Insulin sensitivity or resistance . Clinical evidence demonstrates that poor control over sugar levels can be a ca
Slide 24: Miboko: A Mass-Market Consumer Product
Miboko : A Mass - Market Consumer Product Download the app and On - board Sensor measures metabolic health score Receive report and weekly targets Applicable to over 80 million people in the U.S. with prediabetes as well as general health - conscious individuals, and obesity market.
Slide 25: Miboko: Launch Update
Miboko : Launch Update Marketing activities thus far: restricted mainly to low - key organic social media campaign. Over 5000 registrations during the first few weeks of BETA launch, with more than 60% conversion for on - boarding Large scale marketing campaign planned for 2022 which is intended to
Slide 26: Miboko: Key Competition
Miboko : Key Competition Noom: Over 50 million Subscribers, >$400m Revenues in 2020 5 Miboko USP: A holistic Metabolic health approach to weight loss and better health supported using our proprietary wearable sensor that gives an insight in to what’s really happening inside the body
Slide 27: Miboko: Key Competition
Miboko : Key Competition What about other competition with programs using Invasive 10 - 14 day CGM? Invasive CGM’s require a prescription in the U.S. Skin trauma from Needle and/or adhesive Reports of pain when pulling sensor filament out of arm These factors make invasive sensors challenging for a
Slide 28: Miboko: Key Competition
Miboko : Key Competition Bruising on Skin will make consumer uptake challenging: Example of bruising on skin from application of 6 invasive sensors over a 3 - 4 month period Whilst this is acceptable in the medical space, it poses significant challenges in the consumer space.
Slide 29: Future Product Opportunities Leveraging the BEAT Technology
CONTINUOUS LACTATE MONITORING Assists in threshold maximization in performance athletes Early identification of tissue hypoperfusion or shock for aggressive early resuscitation of critically ill patients to improve the their chances of survival BODY TEMPERATURE MONITORING Gives a more accurate and l
Slide 30: Future Product Opportunities Leveraging the BEAT Technology
ALCOHOL MONITORING Support personal health goals and provide warnings prior to driving. Provide physicians with individual’s drinking habits. Prevention of progression - to - alcohol - related disease DRUG MONITORING Monitoring the impact of drugs and personalized treatment plan for patients. Global
Slide 31: The Team
The Team ▪ We are building a world class team ▪ So far includes senior level appointments, with experience from companies including: Dexcom, Lifescan , Abbvie , & Eli Lilly ▪ Hiring for Chief Marketing and Sales Officers – U.S. and EU
Slide 32: Intellectual Property
Intellectual Property ▪ IP consists of several Filed Patents and substantial know - how ▪ Two key sensor - related patents are not yet published, relating to novel device and composition
Slide 33: Summary
Summary ▪ CE Class 2b Medical Device Approval – and subsequent user testimonials and order for 200,000 sensors (from UK Licensee) and first batch delivery made in December 2021, leading the company to start recognizing revenues for for the first time in its corporate history. ▪ FDA PMA review in pro
Slide 34: References
References 1. https://www.idf.org/aboutdiabetes/what - is - diabetes/facts - figures.html 2. https://drug - dev.com/global - type - 2 - diabetes - market - set - to - almost - double - to - 58 - 7 - billion/ 3. https://www.prnewswire.com/news - releases/global - digital - diabetes - market - outlook
Nemaura Medical — Investor Presentation (February 2022) on 6ix